The Hippo pathway and its key effectors, YAP and TAZ, play a critical role in HSC activation and hepatic fibrosis: YAP inhibition leads to HSC inactivation and hepatic fibrosis reduction5–10. The gene discussed is YAP1; the disease is Hepatic fibrosis.